A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07294625 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: LVIVO-TaVec200 product

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]